Resonance Health Ltd (ASX: RHT) is strengthening its position in the medical imaging sector through the development of a non-invasive MRI-based liver fibrosis assessment device aimed at providing a viable alternative to traditional liver biopsy. The technology is being validated through the DEVIMLA clinical study and is designed to deliver accurate fibrosis and inflammation measurements using standard MRI equipment without the need for contrast agents or specialised hardware. The company believes the solution could address a significant unmet need in chronic liver disease diagnostics, supported by the growing prevalence of liver disorders and increasing demand for non-invasive monitoring tools.
The initiative is aligned with expanding opportunities in the MASH (Metabolic Dysfunction-Associated Steatohepatitis) and GLP-1 therapeutic markets, where imaging-based endpoints are becoming increasingly important. Resonance Health also continues to leverage its established portfolio, including FerriScan®, HepaFatScan®, and body-composition analysis services, while benefiting from a global network of over 400 MRI sites across 48 countries. The company expects its liver fibrosis platform to support future growth alongside its profitable Software-as-a-Medical-Device and clinical trials businesses, with commercialisation targeted in the coming years.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events. Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Resonance Health Advances MRI Liver Fibrosis Platform Amid Growing MASH Opportunity
Resonance Health Ltd (ASX: RHT) is strengthening its position in the medical imaging sector through the development of a non-invasive MRI-based liver fibrosis assessment device aimed at providing a viable alternative to traditional liver biopsy. The technology is being validated through the DEVIMLA clinical study and is designed to deliver accurate fibrosis and inflammation measurements using standard MRI equipment without the need for contrast agents or specialised hardware. The company believes the solution could address a significant unmet need in chronic liver disease diagnostics, supported by the growing prevalence of liver disorders and increasing demand for non-invasive monitoring tools.
The initiative is aligned with expanding opportunities in the MASH (Metabolic Dysfunction-Associated Steatohepatitis) and GLP-1 therapeutic markets, where imaging-based endpoints are becoming increasingly important. Resonance Health also continues to leverage its established portfolio, including FerriScan®, HepaFatScan®, and body-composition analysis services, while benefiting from a global network of over 400 MRI sites across 48 countries. The company expects its liver fibrosis platform to support future growth alongside its profitable Software-as-a-Medical-Device and clinical trials businesses, with commercialisation targeted in the coming years.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events. Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au